← SynDRA
ALTANSERIN
SynDRA canonical compound SYN0002894 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | HTR2A |
|---|
| Mechanism of action | Serotonin receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Serotonin receptor antagonist
- HTR2A INHIBITOR
- HTR2A ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HTR1A
- DRD2
- ALOX15B
- GMNN
- TDP1
- RGS4
- MBNL1
- HPGD
- HDAC6
- EHMT2
- APEX1
- CYP3A4
- CYP2D6
- CYP2C9
- CYP2C19
- CYP1A2
- BAZ2B
- TSHR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT2A
- ACES
- RXFP1
- PHGDH
- NR1I2
- NF2L2
- KCNH2
- KCMB2
- JUN
- HSPB1
- GPR32
- GLI3
- ESRRA
- DRD1
- CP3A7
- CP3A4
- CP2D6
- CP1A2
- CAC1H
- ADRB2
- ACM1
- S12A5
Drug classes
- Contrast Media
- Serotonin Antagonists
Cross-references
Synonyms
- Altanserine
- Altanserina
- ALTANSERIN TARTRATE
- UNII-9P204CHE8J
- Altanserin tartrate [USAN]
- 9P204CHE8J
- Altanserin tartrate (USAN)
- 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
- EINECS 279-159-5
- AC1Q59OU
- AC1MHW43
- SCHEMBL124036
- DTXSID20229675
- 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2-thio-2,4(1H,3H)-quinazolinedione L-(+)-tartrate (1:1)
- D02836
- R-53,200
- 4(1H)-Quinazolinone, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2,3-dihydro-2-thioxo-, (R-(R*,R
- Altanserinum
- R-53200
- RefChem:111472
- DTXCID3023891
- Altanserin [INN]
- NCGC00025302-01
- Altanserine [French]
- Altanserinum [Latin]
- Altanserina [Spanish]
- UNII-5015H744JQ
- EINECS 278-422-1
- Tocris-1809
- ALTANSERIN [WHO-DD]
- SCHEMBL404849
- CHEBI:2613
- orb1698522
- SCHEMBL23326249
- SCHEMBL30136524
- SCHEMBL30136526
- SMYALUSCZJXWHG-UHFFFAOYSA-N
Look up ALTANSERIN in the interactive SynDRA portal →